334 related articles for article (PubMed ID: 32796077)
1. A Mechanism-Based Targeted Screen To Identify Epstein-Barr Virus-Directed Antiviral Agents.
Li X; Akinyemi IA; You JK; Rezaei MA; Li C; McIntosh MT; Del Poeta M; Bhaduri-McIntosh S
J Virol; 2020 Oct; 94(21):. PubMed ID: 32796077
[TBL] [Abstract][Full Text] [Related]
2. Epstein-Barr Virus (EBV)-Related Lymphoproliferative Disorders in Ataxia Telangiectasia: Does ATM Regulate EBV Life Cycle?
Tatfi M; Hermine O; Suarez F
Front Immunol; 2018; 9():3060. PubMed ID: 30662441
[TBL] [Abstract][Full Text] [Related]
3. Role of ATM in the formation of the replication compartment during lytic replication of Epstein-Barr virus in nasopharyngeal epithelial cells.
Hau PM; Deng W; Jia L; Yang J; Tsurumi T; Chiang AK; Huen MS; Tsao SW
J Virol; 2015 Jan; 89(1):652-68. PubMed ID: 25355892
[TBL] [Abstract][Full Text] [Related]
4. Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in vitro and in vivo: a potential method for treating EBV-positive malignancies.
Westphal EM; Blackstock W; Feng W; Israel B; Kenney SC
Cancer Res; 2000 Oct; 60(20):5781-8. PubMed ID: 11059774
[TBL] [Abstract][Full Text] [Related]
5. TLR9 triggering in Burkitt's lymphoma cell lines suppresses the EBV BZLF1 transcription via histone modification.
Zauner L; Melroe GT; Sigrist JA; Rechsteiner MP; Dorner M; Arnold M; Berger C; Bernasconi M; Schaefer BW; Speck RF; Nadal D
Oncogene; 2010 Aug; 29(32):4588-98. PubMed ID: 20514021
[TBL] [Abstract][Full Text] [Related]
6. Immune activation suppresses initiation of lytic Epstein-Barr virus infection.
Ladell K; Dorner M; Zauner L; Berger C; Zucol F; Bernasconi M; Niggli FK; Speck RF; Nadal D
Cell Microbiol; 2007 Aug; 9(8):2055-69. PubMed ID: 17419714
[TBL] [Abstract][Full Text] [Related]
7. Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas.
Feng WH; Hong G; Delecluse HJ; Kenney SC
J Virol; 2004 Feb; 78(4):1893-902. PubMed ID: 14747554
[TBL] [Abstract][Full Text] [Related]
8. Antiviral agent cidofovir decreases Epstein-Barr virus (EBV) oncoproteins and enhances the radiosensitivity in EBV-related malignancies.
Abdulkarim B; Sabri S; Zelenika D; Deutsch E; Frascogna V; Klijanienko J; Vainchenker W; Joab I; Bourhis J
Oncogene; 2003 Apr; 22(15):2260-71. PubMed ID: 12700662
[TBL] [Abstract][Full Text] [Related]
9. Viral response to chemotherapy in endemic burkitt lymphoma.
Tang W; Harmon P; Gulley ML; Mwansambo C; Kazembe PN; Martinson F; Wokocha C; Kenney SC; Hoffman I; Sigel C; Maygarden S; Hoffman M; Shores C
Clin Cancer Res; 2010 Apr; 16(7):2055-64. PubMed ID: 20233888
[TBL] [Abstract][Full Text] [Related]
10. Spectrum of Epstein-Barr virus-associated diseases.
Kutok JL; Wang F
Annu Rev Pathol; 2006; 1():375-404. PubMed ID: 18039120
[TBL] [Abstract][Full Text] [Related]
11. The lytic phase of epstein-barr virus requires a viral genome with 5-methylcytosine residues in CpG sites.
Kalla M; Göbel C; Hammerschmidt W
J Virol; 2012 Jan; 86(1):447-58. PubMed ID: 22031942
[TBL] [Abstract][Full Text] [Related]
12. Ceramide promotes lytic reactivation of Epstein-Barr virus in gastric carcinoma.
Kim JY; Min YJ; Lee M-H; An YR; Ashktorab H; Smoot DT; Kwon SW; Lee SK
J Virol; 2024 Feb; 98(2):e0177623. PubMed ID: 38197630
[TBL] [Abstract][Full Text] [Related]
13. Resveratrol inhibits proliferation and survival of Epstein Barr virus-infected Burkitt's lymphoma cells depending on viral latency program.
De Leo A; Arena G; Stecca C; Raciti M; Mattia E
Mol Cancer Res; 2011 Oct; 9(10):1346-55. PubMed ID: 21856773
[TBL] [Abstract][Full Text] [Related]
14. Development of a high-throughput screen for inhibitors of Epstein-Barr virus EBNA1.
Thompson S; Messick T; Schultz DC; Reichman M; Lieberman PM
J Biomol Screen; 2010 Oct; 15(9):1107-15. PubMed ID: 20930215
[TBL] [Abstract][Full Text] [Related]
15. Epstein-Barr virus latency: LMP2, a regulator or means for Epstein-Barr virus persistence?
Longnecker R
Adv Cancer Res; 2000; 79():175-200. PubMed ID: 10818681
[TBL] [Abstract][Full Text] [Related]
16. Suberoylanilide hydroxamic acid induces viral lytic cycle in Epstein-Barr virus-positive epithelial malignancies and mediates enhanced cell death.
Hui KF; Chiang AK
Int J Cancer; 2010 May; 126(10):2479-89. PubMed ID: 19816947
[TBL] [Abstract][Full Text] [Related]
17. Aspirin induces lytic cytotoxicity in Epstein-Barr virus-positive cells.
Liu SF; Wang H; Li ZJ; Deng XY; Xiang H; Tao YG; Li W; Tang M; Cao Y
Eur J Pharmacol; 2008 Jul; 589(1-3):8-13. PubMed ID: 18571159
[TBL] [Abstract][Full Text] [Related]
18. Multiple Viral microRNAs Regulate Interferon Release and Signaling Early during Infection with Epstein-Barr Virus.
Bouvet M; Voigt S; Tagawa T; Albanese M; Chen YA; Chen Y; Fachko DN; Pich D; Göbel C; Skalsky RL; Hammerschmidt W
mBio; 2021 Mar; 12(2):. PubMed ID: 33785626
[TBL] [Abstract][Full Text] [Related]
19. Induction of Epstein-Barr virus (EBV) reactivation in Raji cells by doxorubicin and cisplatin.
Hsu CH; Hergenhahn M; Chuang SE; Yeh PY; Wu TC; Gao M; Cheng AL
Anticancer Res; 2002; 22(6C):4065-71. PubMed ID: 12553034
[TBL] [Abstract][Full Text] [Related]
20. Transcriptome analysis of Burkitt lymphoma cells treated with anti-convulsant drugs that are inhibitors of Epstein-Barr virus lytic reactivation.
Gorres KL; Reineke DM; Miller G
PLoS One; 2024; 19(4):e0299198. PubMed ID: 38635661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
